Skip to main content
PMC home page
Vaccines logoLink to Vaccines
. 2014 Jul 15;2(3):549–562. doi: 10.3390/vaccines2030549

Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification

Zhi-Hua Huang 1, Zhan-Yi Sun 1, Yue Gao 1, Pu-Guang Chen 1, Yan-Fang Liu 1, Yong-Xiang Chen 1, Yan-Mei Li 1,*
PMCID: PMC4494217  PMID: 26344745

Abstract

Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

Keywords: tumor, vaccine, multi-component, multivalency, nano-size

1. Introduction

Tumor is one of the most dangerous diseases all over the world. Traditional therapies, such as surgery, chemotherapy and radiotherapy, are not always effective and may lead to serious side-effects. Therefore, immunotherapy is considered to be safer and more effective as a promising therapy [1].

In recent years, several kinds of immunotherapies have been focused on. Activated lymphocytes in vitro or antibodies are transported into patients to progress passive immunotherapy. Some immune-related molecules, such as IL-2, are used for activating the immune system as nonspecific immunostimulatory agents [2]. Synthetic tumor vaccines have also been developed to elicit an antigen-specific immune response to remove tumor tissue and to improve the quality of lives of patients [3].

2. The Challenges of Synthetic Tumor Vaccines

The first challenge of synthetic vaccines against tumor is to find the “right antigens” as targets [3]. Unlike tumors caused by oncogenic virus, such as human papillomavirus, which expresses specific virus-associated antigens, many kinds of tumor cells express self-antigens at higher levels. Therefore, a perfect tumor vaccine should elicit an immune response that could not only specifically recognize and kill the tumor cells, but also avoid the autoimmune responses. In some kinds of vaccines, extracts of tumor tissue or inactivated tumor cells are directly used as a kit of antigens [4].

Tumor antigens can be sorted into two parts, tumor-specific antigens, which only express on tumor cells, and tumor-associated antigens, which also express on the surface of normal cells at lower levels, such as glycoproteins and glycolipids [5,6]. Tumor-associated antigens are widely focused on in synthetic tumor vaccines, especially carbohydrates, glycoproteins and glycopeptides. Glycosylation is a kind of important modification associated with the processes of cell-cell interaction, immunological recognition and cell-vessel adhesion. Many specific changes of carbohydrate structures are observed during tumor progression. Therefore, glycoproteins and carbohydrates may be the potential targets of the design of tumor vaccines. There are many kinds of tumor-associated carbohydrate antigens and glycoprotein antigens. Carbohydrate antigens, such as Tn, TF, STn, GM2, Globo H, PsialA, Gb3, Ley, GM3, STn and ST, are widely focused on in the development of tumor vaccines [7,8]. The appearance of these antigens may be due to the upregulation or downregulation of different glycosylation-associated enzymes in tumor cells. MUC1 is a well-known tumor-associated glycoprotein antigen, which is overexpressed in many epithelial adenomas, such as colon, prostate, ovary and breast [9]. Moreover, overexpression of MUC1 on tumor cells is associated with tumor metastasis [10,11,12,13]. In tumor cells, MUC1 distributes on all surfaces of the cells. By contrast, MUC1 only expresses on the free surface of normal cells [14].

The second challenge of synthetic vaccines against tumor is to elicit a high immune response against a certain antigen. Tumor cells may escape the immunological surveillance and cause immunological tolerance during tumor progression. Because of immunological tolerance to tumor antigens, the immunogenicity of the self-antigen, especially small carbohydrates and glycopeptides in synthetic vaccines, is too weak to elicit a robust immune response. Therefore, besides the specificity, vaccines need to be powerful enough to break the tolerance and rebuild surveillance, which is important for long-term protection [15]. An adjuvant is also added to the vaccine dose to improve the immunogenicity of the antigen, providing vaccine delivery and an immunostimulator, such as Freund’s Adjuvant, MF59 emulsion, QS-21 and aluminum adjuvant [16]. Improving the immunogenicity of the antigen is a main aim of vaccine design.

3. Multi-Component Vaccine

3.1. Carrier Proteins in Vaccine Design

Carrier proteins are widely used in commercially available combined vaccines. Carrier proteins, which have lots of antigens, are highly immunogenic. Therefore, the conjugation of antigens with carrier proteins, such as bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH) and tetanus toxoid (TT), could improve immune response against the desired antigens. Kunz and co-workers conjugated TF-modified or STn-modified MUC1 glycopeptide to TT and found that these conjugates elicited a high-level immune response [17,18]. The IgG antibody elicited by these vaccines recognized not only tumor cells, but also tumor tissues from patients [19]. Li and co-workers conjugated a series of MUC1 glycopeptides to BSA as vaccine candidates and found that glycosylation at the Thr residue in the PDTRP domain played important roles in eliciting the immune response (Figure 1) [20]. However, carrier proteins often elicit a high-level of immune response against themselves, which is probably not useful for immunotherapy against the desired antigens.

Figure 1.

Figure 1

Open in a new tab

Li’s vaccine consisting of the glycopeptide antigen and the T-cell epitope [20].

3.2. T-Cell Epitope in Vaccine Design

Immunological research indicates some important processes in the pathway of immune responses. The B-cell epitope is recognized by the B-cell receptor (BCR) on the surface of B-lymphocytes to elicit a fast, low-level immune response to produce a low-affinity IgM antibody. However, activation of T-helper cells is necessary in the affinity maturation and class switch of antibodies. Therefore, the T-helper cell epitope is a potential component for improving the immune response by T-cell activation. Based on these previous studies, a more rational structure can be designed [21].

Kunz and co-workers designed a two-component vaccine conjugating MUC1 glycopeptide with the T-cell epitope from carrier proteins using a flexible spacer [22,23]. The same strategy was used to synthesize vaccines consisting of different glycosylated MUC1 peptides. Vaccines of glycosylated MUC1 with STn on the Thr site in the PDTRP motif elicited the highest titer [24]. Li and co-workers synthesized vaccines consisting of 20-residue MUC1 glycopeptide and different T-cell epitopes from tetanus toxoid. Immunological evaluation demonstrated that the FNNFTVSFWLRVPKVSASHLE sequence could adjuvant the MUC1 glycopeptide to elicit a higher-level immune response without extra adjuvant (Figure 2) [25].

Figure 2.

Figure 2

Open in a new tab

Li’s vaccine consisting of the glycopeptide antigen and the T-cell epitope [25].

3.3. Toll-Like Receptor Agonist in Vaccine Design

The Toll-like receptor (TLR) in mammals is a kind of receptor that recognizes pathogen-associated molecular patterns (PAMPs) [26,27]. Agonist recognized by TLR may activate the pathway to regulate the expression of immune-related genes to activate the innate immune system and, consequently, the adaptive immune system [28,29,30]. Therefore, the TLR agonist can be used as an adjuvant in vaccine design. There are several kinds of TLRs that could recognize different agonists [28].

Guo and co-workers designed a vaccine consisting of a GM3 carbohydrate antigen and monophosphoryl lipid A, an agonist of TLR4 from the cell wall of Gram-negative bacteria (Figure 3) [31,32].

Figure 3.

Figure 3

Open in a new tab

Guo’s vaccine consisting of the carbohydrate antigen and the TLR4 agonist [31].

Lipopeptide from bacteria is a kind of TLR2 agonists that can be used as a building block in the synthesis of vaccines [33]. Boons and co-workers built an exciting structure consisting of a bacterial lipopeptide of Pam3CSKKKK, a short MUC1 glycopeptide as the B-cell epitope and a T-helper cell epitope of KLFAVWKITYKDT from poliovirus (Figure 4). The vaccine was immunized in liposome, eliciting specific and effective immune responses [34,35]. The uptake process of vaccines by the HEK293T cell line was obviously improved by the transfection of the TLR2 gene, which proved the functions of lipopeptide in the vaccine. Furthermore, the vaccine was proven to be capable of slowing the growth of xenograft tumor [36]. Payne and co-workers synthesized tumor vaccines containing per-glycosylated MUC1 glycopeptide and lipopeptide of Pam3CS with an efficient condensation reaction, and they demonstrated that different glycosylations affected the immune response [37]. Kunz and co-workers constructed vaccines containing Pam3CKKKK and MUC1 glycopeptide, which elicited a good immune response [38]. Li and co-workers developed the method of thioether ligation to ligate peptide and Pam3CKKKK, and they synthesized a series of two-component and three-component vaccines. These vaccines improved the immune response against antigens and killed tumor cells by complement-dependent cytotoxicity (CDC) [39]. Toth and co-workers developed an oligomer of lipoamino acid as the agonist of TLR2 and further synthesized vaccines, including carbohydrate antigens and this agonist [40].

Figure 4.

Figure 4

Open in a new tab

Boons’ vaccine consisting of the glycopeptide and the TLR2 agonist [34].

Sucheck and co-workers designed multi-component vaccines in a different way [41,42]. When antigens are seized by antibodies, Fc domains of antibodies will interact with Fc receptors of phagocytes and induce the process of uptake, degradation and presentation of antigens. Therefore, Sucheck and co-workers first used a vaccine to elicit a high-level immune response against an unrelated antigen of l-rhamnose. This kind of antibodies can improve the presentation of l-rhamnose-containing three-component antigens by interactions between antibodies and carbohydrates and interactions between the Fc domains of antibodies and the Fc receptors of phagocytes.

4. Multivalency in Vaccine Design

The multi-component strategy is used to combine the components involved in different processes in the activation of the immune system. Moreover, multivalency is developed to achieve a cluster of antigens. It has been proven that cluster antigens could elicit a higher-level immune response than separated antigens, and antibodies recognized cluster antigens much better than separated ones [43,44,45]. Therefore, multivalency is another effective strategy to improve the efficiency of vaccines by combining several antigens in a single vaccine macromolecule [46]. Carrier proteins always bear several antigens in a single protein molecule, but it is hard to isolate a pure conjugate bearing a certain number of antigens.

Danishyfsky and co-workers designed a vaccine containing several kinds of carbohydrate antigens of Globo-H, STn, Tn, Lewisy and TF in a linear backbone (Figure 5) [47,48,49,50]. In addition, a vaccine containing alternate Gb3 carbohydrate and an MUC5Ac T-helper cell epitope was designed to improve the immune response and specificity [51].

Figure 5.

Figure 5

Open in a new tab

The structure of a linear multivalent vaccine.

Besides the linear backbone, cyclopeptide is also a useful template of multivalent vaccines, which can be formed by increasing the tendency of cyclization by proline [52] or the alternate sequence of l- and d-amino acid residues [53]. Danishyfsky and co-workers constructed a multivalent carbohydrate antigen on the cyclopeptide template and fixed the orientation of carbohydrate antigens by olefin metathesis (Figure 6) [54]. Dumy and co-workers designed a four-component vaccine consisting of multivalent carbohydrates on cyclopeptide, a T-helper cell epitope, a cytotoxic T-cell epitope and the TLR2 agonist [55]. This vaccine simultaneously elicited a humoral and cellular immune response, resulting in the suppression of the growth of MO5 xenograft tumor.

Figure 6.

Figure 6

Open in a new tab

Multivalent template of a cyclopeptide.

Polylysine is also a template of multivalent structures. The number of amino group in the template could be doubled when adding another lysine to the template [56]. Li and co-workers designed four-valent vaccines by conjugating MUC1 peptide to a polylysine template with the reaction of azide-alkyne cycloaddition (Figure 7) [57,58].

Figure 7.

Figure 7

Open in a new tab

Multivalent template of polylysine.

Spadoro and co-workers designed four-valent and eight-valent vaccines using calixarene to present the PDTRP motif from MUC1. The TLR2 agonist was introduced to the template by the ether group, and the vaccine produced antibodies against the PDTRP motif (Figure 8) [59].

Figure 8.

Figure 8

Open in a new tab

Multivalent template of calixarene.

Polymers modified with functional groups also become a potential multivalent vaccine template. In this template, different monomers, various degrees of polymerization, block copolymerization and modifications can be employed to construct different vaccine structures. Kunz and co-workers synthesized poly(HPMA) and conjugated MUC1 glycopeptide, a T-helper cell epitope and lauric acid [60].

5. Antigen Modification

Vaccines with natural antigens often elicit a weak immune response, due to their structural characteristics or immunological tolerance. Therefore, besides the structural design of vaccines, strategies of antigen modification have been developed to enhance the immune response.

5.1. Modification in Vitro

A designed vaccine containing unnatural antigen is a powerful method to overcome the low immunogenicity or immune tolerance of natural antigens, which needs cross-recognition between antibodies elicited by unnatural antigens and natural antigens. Ye and co-workers synthesized kinds of modified STn antigens and found that fluorine modification enhanced the immunogenicity of the STn antigen [61]. The challenge of this strategy is to keep enough specificity of immune response against the desired antigens when analogs are used to elicit the immune response instead.

5.2. Modification in Vivo

Another interesting strategy for antigen modification is to modify antigens on the surface of tumor cells and then elicit the immune response to kill tumor cells with modified antigens. Schultz and co-workers designed a bifunctional molecule containing a 2,4-dinitrophenyl group and a specific ligand of a prostate-specific membrane antigen. This bifunctional molecule modified the prostate tumor cells with the highly immunogenic 2,4-dinitrophenyl group. A 2,4-dinitrophenyl vaccine was used to elicit the immune response to kill modified tumor cells [62]. Guo and co-workers modified the natural GM3 antigen by GM3NPhAc with a substrate of ManNPhAc by glycoengineering technology in vivo. Additionally, GM3NPhAc vaccines were applied to target modified tumor cells in mice models [63]. This strategy allows researchers to modify antigens with a simpler route or simpler substrates, improving “missiles” and “targets” in the same battle.

6. Conclusions and Perspective

Tumor vaccine is a promising strategy against tumor, which could elicit a systemic immune response to recognize and kill tumor cells and provide long-term specific protection for the body. Specificity and efficiency are the most critical problems to be overcome. Synthetic tumor vaccines showed their advantages in the design and optimization of tumor vaccines, and some effective strategies have been developed. However, immune response is a systemic result of complex interactions between molecules, cells, tissues and organs. It is too hard to forecast exactly the final effects of a certain vaccine. However, there are some principles that have been achieved, which could be used as references in vaccine design. T-cell activation is a key step for humoral immune response, so lack of T-cell epitope in vaccines may mainly cause the production of IgM antibody according to a T-cell-independent pathway [64]. T-cell response is regulated by the balance between co-stimulatory signals and immune check points, which apply contrary signals of stimulation and inhibition [65]. The differentiation of naive T-cells to different subtypes is regulated by cytokines and antigens, which affects the characteristics of immune response. The activation of the innate immune response could consequently activate the adaptive immune response, such as using TLR agonists. Tumor vaccines need to target different antigens or different immune-related pathways and elicit different types of immune responses, such as the humoral versus cellular response and activation of type 1 versus type 2 T-helper cell. A combination of different input immune-related components to optimize the output immune response is an important principle in vaccine design [16].

More than ten kinds of TLRs agonists were studied, such as imidazoquinoline, loxoribine, bropirimine for TLR7 and CpG DNA for TLR9. Many studies provided promising agonists for designing tumor vaccines [28,66]. Besides, it is worth noting that certain functional groups of agonists should stay free to remain their activities in the immune process [67]. Agonists of stimulatory receptors and antagonists of checkpoints, which have been proven to enhance the antitumor activity of other therapies, could be used as potential components of antitumor vaccines, such as inhibitors of PD1 and CTLA4 [68,69,70]. In addition, new templates could be used as multivalent tumor vaccines, such as carbohydrates with several hydroxyl groups [67,71,72]. Besides the design of single vaccine molecules that we discussed before, the size effect is also critical in the immune response by affecting the processes of antigen delivery, lasting antigen release, antigen presentation by antigen-presenting cells (APCs) and antigen cross-presentation [73]. Several studies have proven that vaccines with a relatively large size can have a stronger interaction with APCs, such as antigens of whole cells, virus-like particles and liposome delivery [74]. In fact, nanosized particles can be formed with traditional adjuvants, such as Freund’s adjuvant, aluminum adjuvant and liposome. Here, we just mentioned the nano-size behavior of vaccine molecules, but not with an additive [75,76,77,78,79,80,81]. Unlike carrier proteins, a proper nanosized system in tumor vaccines needs to elicit almost no immune response against itself. In the future, more attention should be paid to develop more rational and effective strategies for vaccine design to improve and strengthen the immune response and to modulate the characteristics of the immune response.

Acknowledgments

This work was supported by the Major State Basic Research Development Program of China (2013CB910700) and (2012CB821600), the National Natural Science Foundation of China (21332006, 91313301) and the Research Project of the Chinese Ministry of Education (113005A).

Author Contributions

Zhi-Hua Huang wrote the introduction and the section of the challenges of synthetic tumor vaccines. Zhan-Yi Sun wrote the section of multi-component vaccine. Yue Gao wrote the section of multivalency in vaccine design. Pu-Guang Chen wrote the section of antigen modification. Yan-Fang Liu wrote the section of conclusions and perspective. Yong-Xiang Chen critically read the review. Yan-Mei Li critically read the review and was responsible for the final submission.

Conflicts of Interest

The authors declare no conflict of interest.

References

  • 1.Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–489. doi: 10.1038/nature10673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Waldmann T.A. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006;6:595–601. doi: 10.1038/nri1901. [DOI] [PubMed] [Google Scholar]
  • 3.Pejawar-Gaddy S., Finn O.J. Cancer vaccines: Accomplishments and challenges. Crit. Rev. Oncol. Hematol. 2008;67:93–102. doi: 10.1016/j.critrevonc.2008.02.010. [DOI] [PubMed] [Google Scholar]
  • 4.Ward S., Casey D., Labarthe M.C., Whelan M., Dalgleish A., Pandha H., Todryk S. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 2002;51:351–357. doi: 10.1007/s00262-002-0286-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wang R.F., Rosenberg S.A. Human tumor antigens for cancer vaccine development. Immunol. Rev. 1999;170:85–100. doi: 10.1111/j.1600-065X.1999.tb01331.x. [DOI] [PubMed] [Google Scholar]
  • 6.Karsten U., von Mensdorff-Pouilly S., Goletz S. What makes muc1 a tumor antigen? Tumor Biol. 2005;26:217–220. doi: 10.1159/000086956. [DOI] [PubMed] [Google Scholar]
  • 7.Guo Z., Wang Q. Recent development in carbohydrate-based cancer vaccines. Curr. Opin. Chem. Biol. 2009;13:608–617. doi: 10.1016/j.cbpa.2009.08.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Galonic D.P., Gin D.Y. Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines. Nature. 2007;446:1000–1007. doi: 10.1038/nature05813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Beatson R.E., Taylor-Papadimitriou J., Burchell J.M. MUC1 immunotherapy. Immunotherapy. 2010;2:305–327. doi: 10.2217/imt.10.17. [DOI] [PubMed] [Google Scholar]
  • 10.Wesseling J., van der Valk S.W., Vos H.L., Sonnenberg A., Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 1995;129:255–265. doi: 10.1083/jcb.129.1.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Takada A., Ohmori K., Yoneda T., Tsuyuoka K., Hasegawa A., Kiso M., Kannagi R. Contribution of carbohydrate antigens sialyl Lewis a and sialyl lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 1993;53:354–361. [PubMed] [Google Scholar]
  • 12.Senapati S., Das S., Batra S.K. Mucin-interacting proteins: From function to therapeutics. Trends Biochem. Sci. 2010;35:236–245. doi: 10.1016/j.tibs.2009.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Li Y.Q., Liu D., Chen D.S., Kharbanda S., Kufe D. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene. 2003;22:6107–6110. doi: 10.1038/sj.onc.1206732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Singh R., Bandyopadhyay D. Muc1—A target molecule for cancer therapy. Cancer Biol. Ther. 2007;6:481–486. doi: 10.4161/cbt.6.4.4201. [DOI] [PubMed] [Google Scholar]
  • 15.Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002;3:991–998. doi: 10.1038/ni1102-991. [DOI] [PubMed] [Google Scholar]
  • 16.Guy B. The perfect mix: Recent progress in adjuvant research. Nat. Rev. Microbiol. 2007;5:505–517. doi: 10.1038/nrmicro1681. [DOI] [PubMed] [Google Scholar]
  • 17.Kaiser A., Gaidzik N., Westerlind U., Kowalczyk D., Hobel A., Schmitt E., Kunz H. A synthetic vaccine consisting of a tumor-associated sialyl-T-N-MUC1 tandem-repeat glycopeptide and tetanus toxoid: Induction of a strong and highly selective immune response. Angew. Chem. Int. Ed. 2009;48:7551–7555. doi: 10.1002/anie.200902564. [DOI] [PubMed] [Google Scholar]
  • 18.Hoffmann-Roder A., Kaiser A., Wagner S., Gaidzik N., Kowalczyk D., Westerlind U., Gerlitzki B., Schmitt E., Kunz H. Synthetic antitumor vaccines from tetanus toxoid conjugates of Muc1 glycopeptides with the Thomsen-Friedenreich antigen and a Fluorine-Substituted analogue. Angew. Chem. Int. Ed. 2010;49:8498–8503. doi: 10.1002/anie.201003810. [DOI] [PubMed] [Google Scholar]
  • 19.Gaidzik N., Kaiser A., Kowalczyk D., Westerlind U., Gerlitzki B., Sinn H.P., Schmitt E., Kunz H. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues. Angew. Chem. Int. Ed. 2011;50:9977–9981. doi: 10.1002/anie.201104529. [DOI] [PubMed] [Google Scholar]
  • 20.Cai H., Huang Z.H., Shi L., Sun Z.Y., Zhao Y.F., Kunz H., Li Y.M. Variation of the glycosylation pattern in MUC1 glycopeptide Bsa vaccines and its influence on the immune response. Angew. Chem. Int. Ed. 2012;51:1719–1723. doi: 10.1002/anie.201106396. [DOI] [PubMed] [Google Scholar]
  • 21.Tam J.P., Lu Y.A. Vaccine engineering—Enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T-cell and B-cell epitopes. Proc. Natl. Acad. Sci. USA. 1989;86:9084–9088. doi: 10.1073/pnas.86.23.9084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Keil S., Claus C., Dippold W., Kunz H. Towards the development of antitumor vaccines: A synthetic conjugate of a tumor-associated MUC1 glycopeptide antigen and a tetanus toxin epitope. Angew. Chem. Int. Ed. 2001;40:366–369. doi: 10.1002/1521-3773(20010119)40:2<366::AID-ANIE366>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  • 23.Dziadek S., Hobel A., Schmitt E., Kunz H. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response. Angew. Chem. Int. Ed. 2005;44:7630–7635. doi: 10.1002/anie.200501594. [DOI] [PubMed] [Google Scholar]
  • 24.Westerlind U., Hobel A., Gaidzik N., Schmitt E., Kunz H. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response. Angew. Chem. Int. Ed. 2008;47:7551–7556. doi: 10.1002/anie.200802102. [DOI] [PubMed] [Google Scholar]
  • 25.Cai H., Chen M.S., Sun Z.Y., Zhao Y.F., Kunz H., Li Y.M. Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid. Angew. Chem. Int. Ed. 2013;52:6106–6110. doi: 10.1002/anie.201300390. [DOI] [PubMed] [Google Scholar]
  • 26.Trinchieri G., Sher A. Cooperation of toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 2007;7:179–190. doi: 10.1038/nri2038. [DOI] [PubMed] [Google Scholar]
  • 27.Lemaitre B. Landmark—The Road to Toll. Nat. Rev. Immunol. 2004;4:521–527. doi: 10.1038/nri1390. [DOI] [PubMed] [Google Scholar]
  • 28.Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004;4:499–511. doi: 10.1038/nri1391. [DOI] [PubMed] [Google Scholar]
  • 29.Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta. 2002;1589:1–13. doi: 10.1016/S0167-4889(01)00182-3. [DOI] [PubMed] [Google Scholar]
  • 30.Akira S., Takeda K., Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat. Immunol. 2001;2:675–680. doi: 10.1038/90609. [DOI] [PubMed] [Google Scholar]
  • 31.Wang Q., Zhou Z., Tang S., Guo Z. Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse. ACS Chem. Biol. 2012;7:235–240. doi: 10.1021/cb200358r. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Erridge C., Bennett-Guerrero E., Poxton I.R. Structure and function of lipopolysaccharides. Microbes Infect. 2002;4:837–851. doi: 10.1016/s1286-4579(02)01604-0. [DOI] [PubMed] [Google Scholar]
  • 33.Reichel F., Roelofsen A.M., Geurts H.P.M., Hamalainen T.I., Feiters M.C., Boons G.J. Stereochemical dependence of the self-assembly of the immunoadjuvants Pam(3)Cys and Pam(3)Cys-Ser. J. Am. Chem. Soc. 1999;121:7989–7997. doi: 10.1021/ja991319q. [DOI] [Google Scholar]
  • 34.Ingale S., Awolfert M., Gaekwad J., Buskas T., Boons G.J. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol. 2007;3:663–667. doi: 10.1038/nchembio.2007.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ingale S., Wolfert M.A., Buskas T., Boons G.J. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting toll-like receptors. Chembiochem. 2009;10:455–463. doi: 10.1002/cbic.200800596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Lakshminarayanan V., Thompson P., Wolfert M.A., Buskas T., Bradley J.M., Pathangey L.B., Madsen C.S., Cohen P.A., Gendler S.J., Boons G.-J. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl. Acad. Sci. USA. 2012;109:261–266. doi: 10.1073/pnas.1115166109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Wilkinson B.L., Day S., Malins L.R., Apostolopoulos V., Payne R.J. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the toll-like receptor 2 agonist Pam(3)Cysser. Angew. Chem. Int. Ed. 2011;50:1635–1639. doi: 10.1002/anie.201006115. [DOI] [PubMed] [Google Scholar]
  • 38.Kaiser A., Gaidzik N., Becker T., Menge C., Groh K., Cai H., Li Y.M., Gerlitzki B., Schmitt E., Kunz H. Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the toll-like receptor 2. Angew. Chem. Int. Ed. 2010;49:3688–3692. doi: 10.1002/anie.201000462. [DOI] [PubMed] [Google Scholar]
  • 39.Cai H., Sun Z.Y., Huang Z.H., Shi L., Zhao Y.F., Kunz H., Li Y.M. Fully synthetic self-adjuvanting thioether-conjugated glycopeptidelipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells. Chem. Eur. J. 2013;19:1962–1970. doi: 10.1002/chem.201203709. [DOI] [PubMed] [Google Scholar]
  • 40.Abdel-Aal A.B., El-Naggar D., Zaman M., Batzloff M., Toth I. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based toll-like receptor 2 ligand. J. Med. Chem. 2012;55:6968–6974. doi: 10.1021/jm300822g. [DOI] [PubMed] [Google Scholar]
  • 41.Sarkar S., Lombardo S.A., Herner D.N., Talan R.S., Wall K.A., Sucheck S.J. Synthesis of a single-molecule l-rhamnose-containing three-component vaccine and evaluation of antigenicity in the presence of anti-l-rhamnose antibodies. J. Am. Chem. Soc. 2010;132:17236–17246. doi: 10.1021/ja107029z. [DOI] [PubMed] [Google Scholar]
  • 42.Sarkar S., Salyer A.C., Wall K.A., Sucheck S.J. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes. Bioconjug. Chem. 2013;24:363–375. doi: 10.1021/bc300422a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kudryashov V., Glunz P.W., Williams L.J., Hintermann S., Danishefsky S.J., Lloyd K.O. Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(Y) conjugates in mice. Proc. Natl. Acad. Sci. USA. 2001;98:3264–3269. doi: 10.1073/pnas.051623598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Zhang S., Walberg L.A., Ogata S., Itzkowitz S.H., Koganty R.R., Reddish M., Gandhi S.S., Longenecker B.M., Lloyd K.O., Livingston P.O. Immune sera and monoclonal antibodies define two configurations for the Sialyl Tn tumor antigen. Cancer Res. 1995;55:3364–3368. [PubMed] [Google Scholar]
  • 45.Nakada H., Inoue M., Numata Y., Tanaka N., Funakoshi I., Fukui S., Mellors A., Yamashina I. Epitopic structure of Tn glycophorin a for an anti-Tn antibody (Mls 128) Proc. Natl. Acad. Sci. USA. 1993;90:2495–2499. doi: 10.1073/pnas.90.6.2495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Yin Z., Comellas-Aragones M., Chowdhury S., Bentley P., Kaczanowska K., Benmohamed L., Gildersleeve J.C., Finn M.G., Huang X. Boosting immunity to small tumor-associated carbohydrates with bacteriophage qbeta capsids. ACS Chem. Biol. 2013;8:1253–1262. doi: 10.1021/cb400060x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ragupathi G., Koide F., Livingston P.O., Cho Y.S., Endo A., Wan Q., Spassova M.K., Keding S.J., Allen J., Ouerfelli O., et al. Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: A synthetic route to anticancer vaccine candidates. J. Am. Chem. Soc. 2006;128:2715–2725. doi: 10.1021/ja057244+. [DOI] [PubMed] [Google Scholar]
  • 48.Keding S.J., Danishefsky S.J. Prospects for total synthesis: A vision for a totally synthetic vaccine targeting epithelial tumors. Proc. Natl. Acad. Sci. USA. 2004;101:11937–11942. doi: 10.1073/pnas.0401894101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lee D., Danishefsky S.J. “Biologic” level structures through chemistry: A total synthesis of a unimolecular pentavalent MUCI glycopeptide construct. Tetrahedron Lett. 2009;50:2167–2170. doi: 10.1016/j.tetlet.2009.02.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Zhu J.L., Wan Q., Lee D., Yang G.B., Spassova M.K., Ouerfelli O., Ragupathi G., Damani P., Livingston P.O., Danishefsky S.J. From synthesis to biologics: Preclinical data on a chemistry derived anticancer vaccine. J. Am. Chem. Soc. 2009;131:9298–9303. doi: 10.1021/ja901415s. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zhu J.L., Wan Q., Ragupathi G., George C.M., Livingston P.O., Danishefsky S.J. Biologics through chemistry: Total synthesis of a proposed dual-acting vaccine targeting ovarian cancer orchestration of oligosaccharide and polypeptide domains. J. Am. Chem. Soc. 2009;131:4151–4158. doi: 10.1021/ja810147j. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Wang J., Li H., Zou G., Wang L.-X. Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study. Org. Biomol. Chem. 2007;5:1529–1540. doi: 10.1039/b702961f. [DOI] [PubMed] [Google Scholar]
  • 53.Ten Cate M.G.J., Severin N., Boerner H.G. Self-assembling peptide-polymer conjugates comprising d-Alt-l)-cyclopeptides as aggregator domains. Macromolecules. 2006;39:7831–7838. doi: 10.1021/ma061738p. [DOI] [Google Scholar]
  • 54.Jeon I., Lee D., Krauss I.J., Danishefsky S.J. A new model for the presentation of tumor-associated antigens and the quest for an anticancer vaccine: A solution to the synthesis challenge via ring-closing metathesis. J. Am. Chem. Soc. 2009;131:14337–14344. doi: 10.1021/ja9052625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Bettahi I., Dasgupta G., Renaudet O., Chentoufi A.A., Zhang X.L., Carpenter D., Yoon S., Dumy P., Benmohamed L. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ Nd CD8+ T Cell Epitopes. Cancer Immunol. Immunother. 2009;58:187–200. doi: 10.1007/s00262-008-0537-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Nardelli B., Lu Y.A., Shiu D.R., Delpierre-Defoort C., Profy A.T., Tam J.P. A chemically defined synthetic vaccine model for HIV-1. J. Immunol. 1992;148:914–920. [PubMed] [Google Scholar]
  • 57.Cai H., Sun Z.Y., Chen M.S., Zhao Y.F., Kunz H., Li Y.M. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: Impact of the cluster effect on the killing of tumor cells. Angew. Chem. Int. Ed. 2014;53:1699–1703. doi: 10.1002/anie.201308875. [DOI] [PubMed] [Google Scholar]
  • 58.Cai H., Huang Z.H., Shi L., Zhao Y.F., Kunz H., Li Y.M. Towards a fully synthetic Muc1-based anticancer vaccine: Efficient conjugation of glycopeptides with Mono-, Di-, and Tetravalent lipopeptides using click chemistry. Chem. Eur. J. 2011;17:6396–6406. doi: 10.1002/chem.201100217. [DOI] [PubMed] [Google Scholar]
  • 59.Geraci C., Consoli G.M., Granata G., Galante E., Palmigiano A., Pappalardo M., di Puma S.D., Spadaro A. First self-adjuvant multicomponent potential vaccine candidates by tethering of four or eight MUC1 antigenic immunodominant PDTRP units on a calixarene platform: Synthesis and biological evaluation. Bioconjug. Chem. 2013;24:1710–1720. doi: 10.1021/bc400242y. [DOI] [PubMed] [Google Scholar]
  • 60.Nuhn L., Hartmann S., Palitzsch B., Gerlitzki B., Schmitt E., Zentel R., Kunz H. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines. Angew. Chem. Int. Ed. 2013;52:10652–10656. doi: 10.1002/anie.201304212. [DOI] [PubMed] [Google Scholar]
  • 61.Yang F., Zheng X.J., Huo C.X., Wang Y., Zhang Y., Ye X.S. Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of Stn antigen. ACS Chem. Biol. 2011;6:252–259. doi: 10.1021/cb100287q. [DOI] [PubMed] [Google Scholar]
  • 62.Dubrovska A., Kim C., Elliott J., Shen W., Kuo T.H., Koo D.I., Li C., Tuntland T., Chang J., Groessl T., et al. A chemically induced vaccine strategy for prostate cancer. ACS Chem. Biol. 2011;6:1223–1231. doi: 10.1021/cb200222s. [DOI] [PubMed] [Google Scholar]
  • 63.Qiu L., Gong X., Wang Q., Li J., Hu H., Wu Q., Zhang J., Guo Z. Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy. Cancer Immunol. Immunother. 2012;61:2045–2054. doi: 10.1007/s00262-012-1224-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Ragupathi G., Liu N.X., Musselli C., Powell S., Lloyd K., Livingston P.O. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol. 2005;174:5706–5712. doi: 10.4049/jimmunol.174.9.5706. [DOI] [PubMed] [Google Scholar]
  • 65.Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012;12:252–264. doi: 10.1038/nrc3239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Li X., Fujio M., Imamura M., Wu D., Vasan S., Wong C.-H., Ho D.D., Tsuji M. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc. Natl. Acad. Sci. USA. 2010;107:13010–13015. doi: 10.1073/pnas.1006662107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Putta M.R., Zhu F.G., Wang D.Q., Bhagat L., Dai M.R., Kandimalla E.R., Agrawal S. Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity. Bioconjug. Chem. 2010;21:39–45. doi: 10.1021/bc900425s. [DOI] [PubMed] [Google Scholar]
  • 68.Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer. 2005;5:263–274. doi: 10.1038/nrc1586. [DOI] [PubMed] [Google Scholar]
  • 69.Robert C., Thomas L., Bondarenko I., O’Day S., Weber J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011;364:2517–2526. doi: 10.1056/NEJMoa1104621. [DOI] [PubMed] [Google Scholar]
  • 70.Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., mcdermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012;366:2443–2454. doi: 10.1056/NEJMoa1200690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Ni J., Powell R., Baskakov I.V., Devico A., Lewis G.K., Wang L.X. Synthesis, conformation, and immunogenicity of monosaccharide-centered multivalent HIV-1 gp41 peptides containing the sequence of DP178. Bioorg. Med. Chem. 2004;12:3141–3148. doi: 10.1016/j.bmc.2004.04.008. [DOI] [PubMed] [Google Scholar]
  • 72.Zhong W., Skwarczynski M., Fujita Y., Simerska P., Good M.F., Toth I. Design and synthesis of lipopeptide-carbohydrate assembled multivalent vaccine candidates using native chemical ligation. Aust. J. Chem. 2009;62:993–999. doi: 10.1071/CH09065. [DOI] [Google Scholar]
  • 73.Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines. 2010;9:1095–1107. doi: 10.1586/erv.10.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Bachmann M.F., Jennings G.T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010;10:787–796. doi: 10.1038/nri2868. [DOI] [PubMed] [Google Scholar]
  • 75.Ghasparian A., Riedel T., Koomullil J., Moehle K., Gorba C., Svergun D.I., Perriman A.W., Mann S., Tamborrini M., Pluschke G., et al. Engineered synthetic virus-like particles and their use in vaccine delivery. Chembiochem. 2011;12:100–109. doi: 10.1002/cbic.201000536. [DOI] [PubMed] [Google Scholar]
  • 76.Boato F., Thomas R.M., Ghasparian A., Freund-Renard A., Moehle K., Robinson J.A. Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system. Angew. Chem. Int. Ed. 2007;46:9015–9018. doi: 10.1002/anie.200702805. [DOI] [PubMed] [Google Scholar]
  • 77.Skwarczynski M., Zaman M., Urbani C.N., Lin I.C., Jia Z.F., Batzloff M.R., Good M.F., Monteiro M.F., Toth I. Polyacrylate dendrimer nanoparticles: A self-adjuvanting vaccine delivery system. Angew. Chem. Int. Ed. 2010;49:5742–5745. doi: 10.1002/anie.201002221. [DOI] [PubMed] [Google Scholar]
  • 78.Kakwere H., Chun C.K.Y., Jolliffe K.A., Payne R.J., Perrier S. Polymer-peptide chimeras for the multivalent display of immunogenic peptides. Chem. Commun. 2010;46:2188–2190. doi: 10.1039/b924112d. [DOI] [PubMed] [Google Scholar]
  • 79.Huang Z.H., Shi L., Ma J.W., Sun Z.Y., Cai H., Chen Y.X., Zhao Y.F., Li Y.M. A totally synthetic, self-assembling, adjuvant-free muc1 glycopeptide vaccine for cancer therapy. J. Am. Chem. Soc. 2012;134:8730–8733. doi: 10.1021/ja211725s. [DOI] [PubMed] [Google Scholar]
  • 80.Skwarczynski M., Toth I. Peptide-based subunit nanovaccines. Curr. Drug Deliv. 2011;8:282–289. doi: 10.2174/156720111795256192. [DOI] [PubMed] [Google Scholar]
  • 81.Parry A.L., Clemson N.A., Ellis J., Bernhard S.S., Davis B.G., Cameron N.R. “Multicopy Multivalent” glycopolymer-stabilized gold nanoparticles as potential synthetic cancer vaccines. J. Am. Chem. Soc. 2013;135:9362–9365. doi: 10.1021/ja4046857. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Vaccines are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES